EASL 2025 Guidelines Target Extrahepatic Cholangiocarcinoma: Imaging, Molecular Typing, and Treatment

EASL 2025 evidence-based guidelines for extrahepatic cholangiocarcinoma (CCA) address early detection, accurate subtype classification (distal vs. perihilar), and integration of molecular profiling into diagnosis and treatment — reflecting real-world clinical management gaps.

• Expert panel commissioned by EASL to draft recommendations covering both distal and perihilar extrahepatic CCA, emphasizing subtype-specific classification systems in light of emerging molecular characterization data.
• Guidelines highlight integration of newer systemic therapies and molecular targets into management algorithms; specific recommendation grades and evidence levels not detailed in the available excerpt.
• Limitation: Only an excerpt of the full guideline was available for review — detailed grading of individual recommendations, specific imaging protocols, and molecular testing thresholds were not extractable from the source snippet.

RadPigeon summaries are original and for information only. They are not clinical advice.